Product Details
Place of Origin: China
Brand Name: Quickoolchem
Payment & Shipping Terms
Minimum Order Quantity: 50 Grams
Price: Negotiable
Packaging Details: 1~10 KG Aluminum Foil Bag, 25KG/drum
Delivery Time: 1-3 working day
Payment Terms: L/C, L/C, D/A, D/P, T/T, Western Union, MoneyGram
Supply Ability: 10 MT/Month
Country Of Origin: |
China |
Cas: |
2349386-89-4 |
Shelf Life: |
2 YEARS |
Service: |
Worldwide |
Molecular Weight: |
329.31 |
Grade: |
Pharmaceutcial Grade |
Molecular Formula: |
C13H19N3O7 |
Test: |
HPLC |
Origin: |
China |
Country Of Origin: |
China |
Cas: |
2349386-89-4 |
Shelf Life: |
2 YEARS |
Service: |
Worldwide |
Molecular Weight: |
329.31 |
Grade: |
Pharmaceutcial Grade |
Molecular Formula: |
C13H19N3O7 |
Test: |
HPLC |
Origin: |
China |
Molnupiravir is an antiviral drug that has gained attention for its potential to treat viral infections, particularly in the context of the COVID-19 pandemic. Molnupiravir has shown broad-spectrum antiviral activity against various RNA viruses, including coronaviruses. Since FIP is caused by a coronavirus, there is a theoretical basis for investigating whether Molnupiravir could inhibit the replication of the virus responsible for FIP.
There are several factors to consider when exploring the use of Molnupiravir for FIP treatment. These include the severity of the disease, the stage at which the cat is diagnosed, potential side effects, and the cost-effectiveness of treatment. Additionally, FIP can manifest in various forms, including wet (effusive) and dry (non-effusive) forms, which may influence treatment strategies.
| Country Of Origin | China |
|---|---|
| Storage | Store In A Cool, Dry Place |
| Shelf Life | 2 YEARS |
| Cas | 2349386-89-4 |
| Grade | Pharmaceutical Grade |
| Service | Worldwide |
| Test | HPLC |
| Molecular Weight | 329.31 |
| Assay | 99.9% |
| Appearance | White Powder |
| EIDD-2801 | Molnupiravir |
| CAS | 2349386-89-4 |
1. Treatment of Viral Infections: Molnupiravir has shown efficacy against a range of RNA viruses, including influenza viruses and coronaviruses like SARS-CoV-2. It can be used to treat viral infections in patients who are symptomatic or at risk of developing severe disease.
2. Antiviral Prophylaxis: Molnupiravir may be used as a prophylactic treatment to prevent viral infections in individuals who are at high risk of exposure, such as healthcare workers or individuals living in close quarters with infected individuals.
3. Pandemic Response: Molnupiravir has garnered significant attention as a potential treatment for pandemics, including the COVID-19 pandemic. Its oral administration and broad-spectrum antiviral activity make it a promising candidate for controlling outbreaks of emerging viral diseases.
4. Research and Development: Molnupiravir powder can also be used in preclinical and clinical research studies to further understand its mechanism of action, assess its efficacy against different viral strains, and explore potential combination therapies.
5. Drug Formulation: Pharmaceutical companies may use Molnupiravir powder as an active pharmaceutical ingredient (API) to formulate oral dosage forms such as tablets, capsules, or oral suspensions for commercial use.
6. Public Health Preparedness: Molnupiravir can contribute to public health preparedness efforts by providing an additional tool for managing viral outbreaks and reducing the burden on healthcare systems during pandemics.
